Results 131 to 140 of about 36,083 (204)

Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors. [PDF]

Nephrol Dial Transplant
Bosi A, Xu Y, Faucon AL, Huang T, Evans M, Shin JI, Fu EL, Carrero JJ.   +7 more
europepmc   +1 more source

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis. [PDF]

Front Pharmacol
He L, Li J, Cheng X, Luo L, Huang Y.
europepmc   +1 more source

Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications. [PDF]

Biomolecules
Kuthati Y, Davuluri VNG, Wong CS.
europepmc   +1 more source

Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. [PDF]

Cureus
Selvaraj V.
europepmc   +1 more source

Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection. [PDF]

Medicina (Kaunas)
Epelde F.
europepmc   +1 more source

Combined Use of Vitamin D and DPP-4 Inhibitors as a Potential Adjuvant Treatment Strategy to Enhance the Efficacy of Novel Beta-Cell Replacement Therapies for Type 1 Diabetes. [PDF]

Med Sci (Basel)
Pinheiro MM, Pinheiro FMM, Di Serio BF, Padilla N, Nwosu BU, Della-Morte D, Ricordi C, Infante M.   +7 more
europepmc   +1 more source

3-(3-Azabicyclo[2, 2, 1]heptan-2-yl)-1,2,4-oxadiazoles as Novel Potent DPP-4 Inhibitors to Treat T2DM. [PDF]

Pharmaceuticals (Basel)
Zinevich TV, Maslov IO, Kirichenko OG, Shorshnev SV, Gureev MA, Dolgushin FM, Porozov YB, Trukhan VM.   +7 more
europepmc   +1 more source

Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Ahmed A, Tan Z, Abd El-Radi W, Rajamani K.   +3 more
europepmc   +1 more source

Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial. [PDF]

Diabetes Obes Metab
Cho YK, Cho JH, Hong SM, Park JH, Lee BW, Yoo JH, Kim JH, Chun SW, Hwang YC, Song KH, Lee WJ.   +10 more
europepmc   +1 more source

Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort study. [PDF]

EClinicalMedicine
Meng LC, Chuang HM, Lai HY, Chen HM, Yang KY, Chen LK, Hsiao FY.   +6 more
europepmc   +1 more source